Description
Product Description:
The first new frontline treatment option for HCC approved in Japan Lenvatinib is a multikinase inhibitor that interrupts the pathways of VEGFR1, VEGFR2, and VEGFR3.It is used in the treatment of differentiated thyroid cancer (DTC), renal Cell Carcinoma, and Hepatocellular Carcinoma (HCC)
Product Features:
Product Name: Lenvaxen
Generic Name: Lenvatinib
Formulation: Capsule
Available Pack Size: 30’s Pot
Available Strength: 4 mg and 10 mg
Registrations: Export Only
Reviews
There are no reviews yet.